Identification of the First Biased NPS Receptor Agonist That Retains Anxiolytic and Memory Promoting Effects with Reduced Levels of Locomotor Stimulation

Overview

Journal Neuropharmacology

Specialties Neurology
Pharmacology

Date 2017 Mar 8

PMID 28267583

Citations 8

Authors

Stewart D Clark

Terrence P Kenakin

Steven Gertz

Carla Hassler

Elaine A Gay

Tiffany L Langston

Rainer K Reinscheid

Scott P Runyon

Affiliations

Soon will be listed here.

Abstract

The neuropeptide S system has been implicated in a number of centrally mediated behaviors including memory consolidation, anxiolysis, and increased locomotor activity. Characterization of these behaviors has been primarily accomplished using the endogenous 20AA peptide (NPS) that demonstrates relatively equal potency for the calcium mobilization and cAMP second messenger pathways at human and rodent NPS receptors. This study is the first to demonstrate that truncations of the NPS peptide provides small fragments that retain significant potency only at one of two single polymorphism variants known to alter NPSR function (NPSR-107I), yet demonstrate a strong level of bias for the calcium mobilization pathway over the cAMP pathway. We have also determined that the length of the truncated peptide correlates with the degree of bias for the calcium mobilization pathway. A modified tetrapeptide analog (4) has greatly attenuated hyperlocomotor stimulation in vivo but retains activity in assays that correlate with memory consolidation and anxiolytic activity. Analog 4 also has a bias for the calcium mobilization pathway, at the human and mouse receptor. This suggests that future agonist ligands for the NPS receptor having a bias for calcium mobilization over cAMP production will function as non-stimulatory anxiolytics that augment memory formation.

Citing Articles

The Influence of the Estrous Cycle on Neuropeptide S Receptor-Mediated Behaviors.

Costa P, Salinas B, Wojciechowski A, Wood S, Runyon S, Clark S J Pharmacol Exp Ther. 2024; 391(3):460-471.

PMID: 39443144 PMC: 11585311. DOI: 10.1124/jpet.124.002415.

Emerging pharmacological targets for alcohol use disorder.

Brockway D, Crowley N Alcohol. 2024; 121:103-114.

PMID: 39069210 PMC: 11638729. DOI: 10.1016/j.alcohol.2024.07.007.

A Role for Neuropeptide S in Alcohol and Cocaine Seeking.

Cannella N, Borruto A, Petrella M, Micioni Di Bonaventura M, Soverchia L, Cifani C Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890099 PMC: 9317571. DOI: 10.3390/ph15070800.

Identification of a Novel Neuropeptide S Receptor Antagonist Scaffold Based on the SHA-68 Core.

Zarkin A, Jahan R, Uprety R, Zhang Y, McElhinny C, Snyder R Pharmaceuticals (Basel). 2021; 14(10).

PMID: 34681248 PMC: 8538004. DOI: 10.3390/ph14101024.

Neuropeptide S Ameliorates Cognitive Impairment of APP/PS1 Transgenic Mice by Promoting Synaptic Plasticity and Reducing Aβ Deposition.

Zhao P, Qian X, Nie Y, Sun N, Wang Z, Wu J Front Behav Neurosci. 2019; 13:138.

PMID: 31293402 PMC: 6603143. DOI: 10.3389/fnbeh.2019.00138.

References

Jarry M, Diallo M, Lecointre C, Desrues L, Tokay T, Chatenet D . The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. Biochem J. 2010; 428(1):113-24. DOI: 10.1042/BJ20090867. View

Boeck C, Martinello C, Castro A, Moretti M, Dos Santos Casagrande T, Guerrini R . Blockade of adenosine A2A receptor counteracts neuropeptide-S-induced hyperlocomotion in mice. Naunyn Schmiedebergs Arch Pharmacol. 2009; 381(2):153-60. DOI: 10.1007/s00210-009-0480-2. View

Mochizuki T, Kim J, Sasaki K . Microinjection of neuropeptide S into the rat ventral tegmental area induces hyperactivity and increases extracellular levels of dopamine metabolites in the nucleus accumbens shell. Peptides. 2010; 31(5):926-31. DOI: 10.1016/j.peptides.2010.02.006. View

Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S . A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci. 2012; 3(3):193-203. PMC: 3369801. DOI: 10.1021/cn200111m. View

Okamura N, Hashimoto K, Iyo M, Shimizu E, Dempfle A, Friedel S . Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(7):1444-8. DOI: 10.1016/j.pnpbp.2007.06.026. View

Bernier V, Stocco R, Bogusky M, Joyce J, Parachoniak C, Grenier K . Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I. J Biol Chem. 2006; 281(34):24704-12. DOI: 10.1074/jbc.M603691200. View

Cline M, Prall B, Smith M, Calchary W, Siegel P . Differential appetite-related responses to central neuropeptide S in lines of chickens divergently selected for low or high body weight. J Neuroendocrinol. 2008; 20(7):904-8. DOI: 10.1111/j.1365-2826.2008.01742.x. View

Jungling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark S . Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron. 2008; 59(2):298-310. PMC: 2610688. DOI: 10.1016/j.neuron.2008.07.002. View

Cline M, Godlove D, Nandar W, Bowden C, Prall B . Anorexigenic effects of central neuropeptide S involve the hypothalamus in chicks (Gallus gallus). Comp Biochem Physiol A Mol Integr Physiol. 2007; 148(3):657-63. DOI: 10.1016/j.cbpa.2007.08.016. View

10.

Gottlieb D, OConnor G, Wilk J . Genome-wide association of sleep and circadian phenotypes. BMC Med Genet. 2007; 8 Suppl 1:S9. PMC: 1995620. DOI: 10.1186/1471-2350-8-S1-S9. View

11.

Reinscheid R, Xu Y, Okamura N, Zeng J, Chung S, Pai R . Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther. 2005; 315(3):1338-45. DOI: 10.1124/jpet.105.093427. View

12.

Black J, Leff P . Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci. 1983; 220(1219):141-62. DOI: 10.1098/rspb.1983.0093. View

13.

Vitale G, Filaferro M, Ruggieri V, Pennella S, Frigeri C, Rizzi A . Anxiolytic-like effect of neuropeptide S in the rat defensive burying. Peptides. 2008; 29(12):2286-91. DOI: 10.1016/j.peptides.2008.08.014. View

14.

Clark S, Tran H, Zeng J, Reinscheid R . Importance of extracellular loop one of the neuropeptide S receptor for biogenesis and function. Peptides. 2009; 31(1):130-8. PMC: 2814945. DOI: 10.1016/j.peptides.2009.10.015. View

15.

Hassler C, Zhang Y, Gilmour B, Graf T, Fennell T, Snyder R . Identification of neuropeptide S antagonists: structure-activity relationship studies, X-ray crystallography, and in vivo evaluation. ACS Chem Neurosci. 2014; 5(8):731-44. PMC: 4140596. DOI: 10.1021/cn500113c. View

16.

Okamura N, Garau C, Duangdao D, Clark S, Jungling K, Pape H . Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain. Neuropsychopharmacology. 2010; 36(4):744-52. PMC: 3037424. DOI: 10.1038/npp.2010.207. View

17.

Liao Y, Lu B, Ma Q, Wu G, Lai X, Zang J . Human Neuropeptide S Receptor Is Activated via a Gαq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues. J Biol Chem. 2016; 291(14):7505-16. PMC: 4817180. DOI: 10.1074/jbc.M115.704122. View

18.

Ehlert F . On the analysis of ligand-directed signaling at G protein-coupled receptors. Naunyn Schmiedebergs Arch Pharmacol. 2008; 377(4-6):549-77. DOI: 10.1007/s00210-008-0260-4. View

19.

Kallupi M, Cannella N, Economidou D, Ubaldi M, Ruggeri B, Weiss F . Neuropeptide S facilitates cue-induced relapse to cocaine seeking through activation of the hypothalamic hypocretin system. Proc Natl Acad Sci U S A. 2010; 107(45):19567-72. PMC: 2984152. DOI: 10.1073/pnas.1004100107. View

20.

Leonard S, Dwyer J, Sukoff Rizzo S, Platt B, Logue S, Neal S . Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl). 2008; 197(4):601-11. DOI: 10.1007/s00213-008-1080-4. View